Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na <superscript>+</superscript> ? - OpacWWW

Tytuł:: Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na ?
Autorzy:: Trum M; Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
Riechel J; Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
Wagner S; Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Jul 26; Vol. 22 (15). Date of Electronic Publication: 2021 Jul 26.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:: Arrhythmias, Cardiac/*drug therapy
Cardiotonic Agents/*therapeutic use
Myocardium/*metabolism
Myocytes, Cardiac/*metabolism
Sodium-Glucose Transporter 2/*metabolism
Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
Animals ; Arrhythmias, Cardiac/metabolism ; Arrhythmias, Cardiac/pathology ; Humans ; Myocardium/pathology ; Myocytes, Cardiac/pathology
References:: J Pharmacol Exp Ther. 2014 Dec;351(3):492-9. (PMID: 25216745)
Basic Res Cardiol. 2011 Mar;106(2):263-72. (PMID: 21174213)
Cardiovasc Res. 1999 Apr;42(1):254-61. (PMID: 10435018)
Diabetes Ther. 2010 Dec;1(2):57-92. (PMID: 22127746)
Circ Res. 2005 Dec 9;97(12):1314-22. (PMID: 16269653)
ESC Heart Fail. 2014 Sep;1(1):26-40. (PMID: 28834665)
Cardiovasc Res. 2013 Sep 1;99(4):600-11. (PMID: 23752976)
Circulation. 2012 Oct 23;126(17):2084-94. (PMID: 23008441)
J Mol Cell Cardiol. 2013 Aug;61:111-22. (PMID: 23570977)
Cardiovasc Res. 2013 Mar 1;97(3):464-71. (PMID: 23213108)
J Physiol. 2015 Mar 15;593(6):1361-82. (PMID: 25772291)
ESC Heart Fail. 2018 Aug;5(4):642-648. (PMID: 30117720)
Am J Physiol Heart Circ Physiol. 2001 Feb;280(2):H738-45. (PMID: 11158973)
Front Pharmacol. 2020 Apr 20;11:413. (PMID: 32372952)
J Mol Cell Cardiol. 2005 Mar;38(3):475-83. (PMID: 15733907)
Circulation. 2010 Apr 13;121(14):1606-13. (PMID: 20351235)
N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602)
Cardiovasc Res. 2019 Sep 1;115(11):1646-1658. (PMID: 30715251)
Int J Cardiol. 2017 Sep 15;243:86-90. (PMID: 28526540)
Front Cardiovasc Med. 2020 Jan 08;6:186. (PMID: 31970162)
J Am Heart Assoc. 2015 Aug 27;4(9):e002183. (PMID: 26316524)
Cardiovasc Res. 1993 Dec;27(12):2229-37. (PMID: 8313433)
Circulation. 1998 Dec 8;98(23):2545-52. (PMID: 9843461)
Cardiovasc Res. 2009 Oct 1;84(1):111-8. (PMID: 19509029)
Cardiovasc Res. 2005 Jan 1;65(1):83-92. (PMID: 15621036)
J Mol Cell Cardiol. 2013 Aug;61:20-7. (PMID: 23727097)
J Pharmacol Exp Ther. 2006 Jul;318(1):214-22. (PMID: 16565163)
Cardiovasc Res. 2003 Mar 15;57(4):1015-24. (PMID: 12650879)
Hypertension. 2003 Dec;42(6):1171-6. (PMID: 14610099)
Circ Res. 2008 Jan 4;102(1):86-94. (PMID: 17967784)
Eur J Heart Fail. 2020 Dec;22(12):2383-2392. (PMID: 33251670)
Circulation. 2020 Apr 14;141(15):1227-1234. (PMID: 31983236)
Cardiovasc Diabetol. 2020 May 28;19(1):69. (PMID: 32466760)
N Engl J Med. 2020 Oct 8;383(15):1413-1424. (PMID: 32865377)
Circ Res. 2012 Sep 28;111(8):1091-106. (PMID: 23023511)
Circ Res. 2002 Aug 23;91(4):278-80. (PMID: 12193459)
Eur J Heart Fail. 2021 Jul;23(7):1217-1225. (PMID: 34051124)
Clin Res Cardiol. 2019 Jun;108(6):577-599. (PMID: 30306295)
JACC Basic Transl Sci. 2019 Feb 25;4(1):27-37. (PMID: 30847416)
J Clin Invest. 2006 Dec;116(12):3127-38. (PMID: 17124532)
Circulation. 2007 Mar 6;115(9):1090-100. (PMID: 17339567)
Br J Pharmacol. 2006 May;148(1):16-24. (PMID: 16520744)
Sci Rep. 2017 Jan 27;7:41166. (PMID: 28128227)
Eur J Heart Fail. 2019 Jul;21(7):862-873. (PMID: 31033127)
Circulation. 2002 May 28;105(21):2543-8. (PMID: 12034663)
J Physiol. 2012 Sep 1;590(17):4289-305. (PMID: 22733660)
Circ Res. 1994 Sep;75(3):443-53. (PMID: 8062418)
J Mol Cell Cardiol. 2010 Jul;49(1):106-12. (PMID: 20026127)
J Pharmacol Exp Ther. 2001 Aug;298(2):469-76. (PMID: 11454907)
Circ Res. 1999 Mar 5;84(4):435-44. (PMID: 10066678)
Heart Fail Rev. 2020 May;25(3):523-535. (PMID: 31701344)
J Mol Cell Cardiol. 2014 Oct;75:206-15. (PMID: 25073061)
Science. 1990 Apr 20;248(4953):376-8. (PMID: 2158147)
Pacing Clin Electrophysiol. 2018 Jun 19;:. (PMID: 29920724)
Am J Hypertens. 2019 Apr 22;32(5):452-459. (PMID: 30689697)
N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608)
Int J Mol Sci. 2019 Sep 06;20(18):. (PMID: 31489895)
Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11282-7. (PMID: 22733741)
Cardiovasc Diabetol. 2021 May 7;20(1):100. (PMID: 33962654)
Circulation. 2021 Jun;143(22):2188-2204. (PMID: 33832341)
Diabetologia. 2018 Mar;61(3):722-726. (PMID: 29197997)
Cardiovasc Res. 2003 Mar 15;57(4):887-96. (PMID: 12650867)
Cardiovasc Res. 2003 Mar 15;57(4):897-912. (PMID: 12650868)
Am J Physiol. 1992 Mar;262(3 Pt 1):C664-71. (PMID: 1312780)
J Biol Chem. 2001 May 25;276(21):17706-11. (PMID: 11279089)
Cardiovasc Res. 2020 Nov 02;:. (PMID: 33135077)
JACC Cardiovasc Imaging. 2021 Feb;14(2):393-407. (PMID: 33129742)
Diabetes Care. 2016 Dec;39(12):e212-e213. (PMID: 27679584)
Circ Res. 1992 Nov;71(5):1231-41. (PMID: 1327577)
J Pharmacol Sci. 2020 Jan;142(1):16-25. (PMID: 31776072)
Circ Res. 2003 May 2;92(8):904-11. (PMID: 12676813)
Cardiovasc Diabetol. 2020 Jun 5;19(1):73. (PMID: 32503541)
N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
Basic Res Cardiol. 2002;97 Suppl 1:I36-42. (PMID: 12479232)
J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S169-S177. (PMID: 16686675)
Cardiovasc Res. 2019 Aug 1;115(10):1533-1545. (PMID: 30649212)
Cardiovasc Res. 2004 Aug 1;63(2):273-82. (PMID: 15249185)
J Diabetes Res. 2018 Oct 4;2018:3106056. (PMID: 30402502)
Cardiovasc Diabetol. 2018 May 22;17(1):73. (PMID: 29788955)
FASEB J. 2011 Dec;25(12):4467-75. (PMID: 21849407)
Circulation. 1999 Apr 27;99(16):2105-12. (PMID: 10217649)
Cell Physiol Biochem. 2013;32(1):25-38. (PMID: 23860121)
Cardiovasc Res. 2021 Apr 01;:. (PMID: 33792689)
Circ Res. 2020 Jan 31;126(3):395-412. (PMID: 31999537)
J Mol Cell Cardiol. 2012 Nov;53(5):593-8. (PMID: 22759452)
Diabetes Care. 2018 Feb;41(2):356-363. (PMID: 29203583)
Circ Res. 2012 Jul 20;111(3):322-32. (PMID: 22723299)
Circ Res. 2011 Mar 4;108(5):555-65. (PMID: 21252154)
Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165729. (PMID: 32068116)
Diabetologia. 2017 Mar;60(3):568-573. (PMID: 27752710)
Pflugers Arch. 2012 Apr;463(4):513-22. (PMID: 22234427)
J Mol Cell Cardiol. 2013 Aug;61:2-10. (PMID: 23608603)
J Am Coll Cardiol. 2000 Aug;36(2):534-40. (PMID: 10933369)
Cardiovasc Diabetol. 2020 Jan 7;19(1):6. (PMID: 31910853)
Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55. (PMID: 23707905)
J Mol Cell Cardiol. 2020 Jul;144:35-46. (PMID: 32418916)
Cardiovasc Diabetol. 2018 Nov 17;17(1):144. (PMID: 30447687)
Diabetes. 2013 Oct;62(10):3324-8. (PMID: 24065789)
Cardiovasc Diabetol. 2019 Feb 2;18(1):15. (PMID: 30710997)
J Biol Chem. 2012 Jun 8;287(24):19856-69. (PMID: 22514276)
Int J Cardiol. 2018 Dec 1;272:260-266. (PMID: 30144995)
Cardiovasc Diabetol. 2019 Nov 28;18(1):165. (PMID: 31779619)
N Engl J Med. 2019 Nov 21;381(21):1995-2008. (PMID: 31535829)
Physiology (Bethesda). 2006 Dec;21:380-7. (PMID: 17119150)
Circ Res. 1999 Apr 2;84(6):713-21. (PMID: 10189359)
Biophys J. 2007 Dec 1;93(11):3835-47. (PMID: 17704163)
J Physiol Sci. 2009 May;59(3):217-25. (PMID: 19340536)
Cardiovasc Diabetol. 2021 Jan 7;20(1):6. (PMID: 33413355)
Front Pharmacol. 2014 Mar 10;5:41. (PMID: 24653702)
J Mol Cell Cardiol. 2014 Nov;76:247-56. (PMID: 25252177)
Diabetes Obes Metab. 2012 Jan;14(1):83-90. (PMID: 21985634)
Circulation. 2002 Jul 23;106(4):447-53. (PMID: 12135944)
J Physiol. 2002 Feb 15;539(Pt 1):133-43. (PMID: 11850507)
Heart. 2006 Jul;92 Suppl 4:iv6-iv14. (PMID: 16775092)
J Mol Cell Cardiol. 2008 Jul;45(1):32-43. (PMID: 18439620)
J Mol Med (Berl). 2011 Jun;89(6):537-43. (PMID: 21279501)
Circ Res. 2001 Jun 8;88(11):1159-67. (PMID: 11397782)
J Am Coll Cardiol. 2021 Jan 26;77(3):243-255. (PMID: 33197559)
Basic Res Cardiol. 2020 Feb 20;115(2):20. (PMID: 32078054)
Circ Res. 2000 Feb 4;86(2):152-7. (PMID: 10666410)
Circulation. 2005 Dec 13;112(24):3738-44. (PMID: 16330684)
Sci Rep. 2020 Oct 9;10(1):17266. (PMID: 33037250)
Cardiovasc Res. 2018 Jan 1;114(1):12-18. (PMID: 29016751)
J Card Fail. 2002 Dec;8(6):416-22. (PMID: 12528095)
Circ Res. 2002 Apr 19;90(7):814-9. (PMID: 11964375)
JACC Basic Transl Sci. 2017 Aug 04;2(4):347-354. (PMID: 30062155)
J Clin Invest. 2009 Apr;119(4):986-96. (PMID: 19273909)
Eur J Heart Fail. 2018 Dec;20(12):1690-1700. (PMID: 30328645)
J Clin Invest. 2010 Oct;120(10):3508-19. (PMID: 20877009)
Circulation. 2012 Jun 5;125(22):2698-706. (PMID: 22565935)
Circ Res. 2005 Sep 16;97(6):558-65. (PMID: 16100047)
Circ Res. 1999 Nov 26;85(11):1009-19. (PMID: 10571531)
Eur J Heart Fail. 2016 Aug;18(8):987-97. (PMID: 27135883)
Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2342-7. (PMID: 19179290)
J Am Soc Nephrol. 2021 Apr 12;:. (PMID: 33846238)
Nat Commun. 2011 Jun 14;2:351. (PMID: 21673672)
ESC Heart Fail. 2020 Sep 18;:. (PMID: 32946200)
Cardiovasc Res. 2010 Jul 1;87(1):50-9. (PMID: 20080988)
Acta Physiol (Oxf). 2006 Nov-Dec;188(3-4):185-93. (PMID: 17054658)
J Appl Toxicol. 2016 Apr;36(4):609-17. (PMID: 26472149)
Am J Physiol Heart Circ Physiol. 2020 Dec 1;319(6):H1347-H1357. (PMID: 33035439)
Pharmacol Res. 2002 Jan;45(1):35-41. (PMID: 11820859)
J Pharm Pharmacol. 2014 Jul;66(7):975-87. (PMID: 24533859)
J Clin Endocrinol Metab. 2012 Mar;97(3):933-42. (PMID: 22170713)
Eur J Heart Fail. 2006 Nov;8(7):673-80. (PMID: 16540370)
Circ Res. 2006 Jul 21;99(2):172-82. (PMID: 16778127)
Cardiovasc Res. 2021 Jan 21;117(2):495-507. (PMID: 32396609)
Pharmacol Res. 2020 Jul;157:104781. (PMID: 32360273)
Contributed Indexing:: Keywords: CaMKII; HFpEF; HFrEF; NHE1; Na+; SGLT2 inhibitor; arrhythmia; heart failure; late INa
Substance Nomenclature:: 0 (Cardiotonic Agents)
0 (SLC5A2 protein, human)
0 (Sodium-Glucose Transporter 2)
0 (Sodium-Glucose Transporter 2 Inhibitors)
Entry Date(s):: Date Created: 20210807 Date Completed: 20210908 Latest Revision: 20210908
Update Code:: 20240105
PubMed Central ID:: PMC8347698
DOI:: 10.3390/ijms22157976
PMID:: 34360742
: Czasopismo naukowe

Pełny tekst

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment strategy for heart failure with reduced ejection fraction (HFrEF) and-depending on the wistfully awaited results of two clinical trials (DELIVER and EMPEROR-Preserved)-may be the first drug class to improve cardiovascular outcomes in patients suffering from heart failure with preserved ejection fraction (HFpEF). Proposed mechanisms of action of this class of drugs are diverse and include metabolic and hemodynamic effects as well as effects on inflammation, neurohumoral activation, and intracellular ion homeostasis. In this review we focus on the growing body of evidence for SGLT2i-mediated effects on cardiac intracellular Na + as an upstream mechanism. Therefore, we will first give a short overview of physiological cardiomyocyte Na + handling and its deterioration in heart failure. On this basis we discuss the salutary effects of SGLT2i on Na + homeostasis by influencing NHE1 activity, late I Na as well as CaMKII activity. Finally, we highlight the potential relevance of these effects for systolic and diastolic dysfunction as well as arrhythmogenesis.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja

Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na + ?